# Alan Boobis

## List of Publications by Citations



| | | | |
|---|---|---|---|
| 257 papers | 13,089 citations | 66 h-index | 103 g-index |
| 293 ext. papers | 14,238 ext. citations | 5.2 avg, IF | 5.92 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 257 | Alternative (non-animal) methods for cosmetics testing: current status and future prospects-2010. *Archives of Toxicology*, **2011**, 85, 367-485 | 5.8 | 398 |
| 256 | IPCS framework for analyzing the relevance of a cancer mode of action for humans. *Critical Reviews in Toxicology*, **2006**, 36, 781-92 | 5.7 | 361 |
| 255 | Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. *Current Drug Metabolism*, **2007**, 8, 33-45 | 3.5 | 349 |
| 254 | Managing the challenge of chemically reactive metabolites in drug development. *Nature Reviews Drug Discovery*, **2011**, 10, 292-306 | 64.1 | 348 |
| 253 | Methods of in vitro toxicology. *Food and Chemical Toxicology*, **2002**, 40, 193-236 | 4.7 | 322 |
| 252 | Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: molecular mechanisms that determine lower expression in cultured cells. *Xenobiotica*, **2002**, 32, 505-20 | 2 | 304 |
| 251 | IPCS framework for analyzing the relevance of a noncancer mode of action for humans. *Critical Reviews in Toxicology*, **2008**, 38, 87-96 | 5.7 | 271 |
| 250 | Systems toxicology: from basic research to risk assessment. *Chemical Research in Toxicology*, **2014**, 27, 314-29 | 4 | 236 |
| 249 | Mode of action in relevance of rodent liver tumors to human cancer risk. *Toxicological Sciences*, **2006**, 89, 51-6 | 4.4 | 220 |
| 248 | Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. *Drug Metabolism and Disposition*, **2003**, 31, 755-61 | 4 | 196 |
| 247 | Risk assessment of combined exposure to multiple chemicals: A WHO/IPCS framework. *Regulatory Toxicology and Pharmacology*, **2011**, 60, S1-S1 | 3.4 | 190 |
| 246 | Cumulative risk assessment of pesticide residues in food. *Toxicology Letters*, **2008**, 180, 137-50 | 4.4 | 190 |
| 245 | New developments in the evolution and application of the WHO/IPCS framework on mode of action/species concordance analysis. *Journal of Applied Toxicology*, **2014**, 34, 1-18 | 4.1 | 188 |
| 244 | Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. *Biochemical Pharmacology*, **1999**, 58, 787-96 | 6 | 188 |
| 243 | Meta-analysis of studies of alcohol and breast cancer with consideration of the methodological issues. *Cancer Causes and Control*, **2006**, 17, 759-70 | 2.8 | 185 |
| 242 | Expression of xenobiotic-metabolizing cytochrome P450 forms in human full-term placenta. *Biochemical Pharmacology*, **1996**, 51, 403-11 | 6 | 182 |
| 241 | Towards microbial fermentation metabolites as markers for health benefits of prebiotics. *Nutrition Research Reviews*, **2015**, 28, 42-66 | 7 | 173 |

| | | | |
|---|---|---|---|
| 240 | Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. *British Journal of Clinical Pharmacology*, **2005**, 60, 107-12 | 3.8 | 165 |
| 239 | Mechanisms of cell death. *Archives of Toxicology*, **1991**, 65, 437-44 | 5.8 | 154 |
| 238 | Risk characterisation of chemicals in food and diet. *Food and Chemical Toxicology*, **2003**, 41, 1211-71 | 4.7 | 147 |
| 237 | Dose-dependent transitions in mechanisms of toxicity: case studies. *Toxicology and Applied Pharmacology*, **2004**, 201, 226-94 | 4.6 | 141 |
| 236 | Dose-dependent transitions in mechanisms of toxicity. *Toxicology and Applied Pharmacology*, **2004**, 201, 203-25 | 4.6 | 137 |
| 235 | Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism. *British Journal of Clinical Pharmacology*, **2003**, 55, 68-76 | 3.8 | 134 |
| 234 | Contribution of CYP1A1 and CYP1A2 to the activation of heterocyclic amines in monkeys and human. *Carcinogenesis*, **1994**, 15, 829-36 | 4.6 | 124 |
| 233 | Expression and localization of CYP3A4 and CYP3A5 in human lung. *American Journal of Respiratory Cell and Molecular Biology*, **1997**, 16, 242-9 | 5.7 | 123 |
| 232 | An approach to investigating the importance of high potency polycyclic aromatic hydrocarbons (PAHs) in the induction of lung cancer by air pollution. *Food and Chemical Toxicology*, **2005**, 43, 1103-16 | 4.7 | 123 |
| 231 | Development of a comprehensive panel of antibodies against the major xenobiotic metabolising forms of cytochrome P450 in humans. *Biochemical Pharmacology*, **1998**, 56, 377-87 | 6 | 117 |
| 230 | Critical analysis of literature on low-dose synergy for use in screening chemical mixtures for risk assessment. *Critical Reviews in Toxicology*, **2011**, 41, 369-83 | 5.7 | 109 |
| 229 | The specificity of inhibition of debrisoquine 4-hydroxylase activity by quinidine and quinine in the rat is the inverse of that in man. *Biochemical Pharmacology*, **1989**, 38, 2795-9 | 6 | 109 |
| 228 | Immunocytochemical localization of cytochrome P-450 in hepatic and extra-hepatic tissues of the rat with a monoclonal antibody against cytochrome P-450 c. *Biochemical Pharmacology*, **1986**, 35, 4543-54 | 6 | 108 |
| 227 | Treatment and removal strategies for estrogens from wastewater. *Environmental Technology (United Kingdom)*, **2008**, 29, 245-67 | 2.6 | 104 |
| 226 | Approaches to carcinogenic risk assessment for polycyclic aromatic hydrocarbons: a UK perspective. *Regulatory Toxicology and Pharmacology*, **2004**, 40, 54-66 | 3.4 | 101 |
| 225 | Global food supply. Reevaluate pesticides for food security and safety. *Science*, **2013**, 341, 717-8 | 33.3 | 96 |
| 224 | Determination of steroid estrogens in wastewater by high performance liquid chromatography-tandem mass spectrometry. *Journal of Chromatography A*, **2007**, 1173, 81-7 | 4.5 | 92 |
| 223 | Pulmonary fibrosis correlates with duration of tissue neutrophil activation. *American Journal of Respiratory and Critical Care Medicine*, **1998**, 158, 620-8 | 10.2 | 92 |

| | | | |
|---|---|---|---|
| 222 | Distribution and induction of CYP3A1 and CYP3A2 in rat liver and extrahepatic tissues. *Biochemical Pharmacology*, **1995**, 50, 2047-56 | 6 | 88 |
| 221 | Scientific principles for the identification of endocrine-disrupting chemicals: a consensus statement. *Archives of Toxicology*, **2017**, 91, 1001-1006 | 5.8 | 86 |
| 220 | Effect of rifampicin and isoniazid on vitamin D metabolism. *Clinical Pharmacology and Therapeutics*, **1982**, 32, 525-30 | 6.1 | 86 |
| 219 | Testicular dysgenesis syndrome and the estrogen hypothesis: a quantitative meta-analysis. *Environmental Health Perspectives*, **2008**, 116, 149-57 | 8.4 | 84 |
| 218 | Induction of cytochrome P450 enzymes in cultured precision-cut human liver slices. *Drug Metabolism and Disposition*, **2003**, 31, 282-8 | 4 | 84 |
| 217 | Identification and location of alpha-helices in mammalian cytochromes P450. *Biochemistry*, **1989**, 28, 3762-70 | 3.2 | 83 |
| 216 | Influence of operating parameters on the biodegradation of steroid estrogens and nonylphenolic compounds during biological wastewater treatment processes. *Environmental Science & Technology*, **2009**, 43, 6646-54 | 10.3 | 81 |
| 215 | Application of key events analysis to chemical carcinogens and noncarcinogens. *Critical Reviews in Food Science and Nutrition*, **2009**, 49, 690-707 | 11.5 | 80 |
| 214 | Evidence for genotoxicity of pesticides in pesticide applicators: a review. *Mutagenesis*, **2006**, 21, 93-103 | 2.8 | 80 |
| 213 | Diazinon is activated by CYP2C19 in human liver. *Toxicology and Applied Pharmacology*, **2001**, 177, 68-76 | 4.6 | 79 |
| 212 | Risk assessment in the 21st century: roadmap and matrix. *Critical Reviews in Toxicology*, **2014**, 44 Suppl 3, 6-16 | 5.7 | 78 |
| 211 | Defective Spermatogenesis: Martin et al. Respond. *Environmental Health Perspectives*, **2008**, 116, | 8.4 | 78 |
| 210 | Species differences in the substrate specificity of hepatic cytochrome P-448 from polycyclic hydrocarbon-treated animals. *Biochemical Pharmacology*, **1979**, 28, 217-26 | 6 | 78 |
| 209 | The Key Events Dose-Response Framework: a cross-disciplinary mode-of-action based approach to examining dose-response and thresholds. *Critical Reviews in Food Science and Nutrition*, **2009**, 49, 682-9 | 11.5 | 77 |
| 208 | Biphasic O-deethylation of phenacetin and 7-ethoxycoumarin by human and rat liver microsomal fractions. *Biochemical Pharmacology*, **1981**, 30, 2451-6 | 6 | 77 |
| 207 | CYP3A7 protein expression is high in a fraction of adult human livers and partially associated with the CYP3A7*1C allele. *Pharmacogenetics and Genomics*, **2005**, 15, 625-31 | 1.9 | 75 |
| 206 | Species differences in the hepatotoxicity of paracetamol are due to differences in the rate of conversion to its cytotoxic metabolite. *Biochemical Pharmacology*, **1987**, 36, 1041-52 | 6 | 74 |
| 205 | Benchmark dose (BMD) modeling: current practice, issues, and challenges. *Critical Reviews in Toxicology*, **2018**, 48, 387-415 | 5.7 | 73 |

| | | | |
|---|---|---|---|
| 204 | Orientation of cytochromes P450 in the endoplasmic reticulum. *Biochemistry*, **1991**, 30, 71-6 | 3.2 | 73 |
| 203 | Cruciferous vegetable consumption alters the metabolism of the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in humans. *Carcinogenesis*, **2004**, 25, 1659-69 | 4.6 | 72 |
| 202 | Comparative studies on the cytochrome p450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems. *Drug Metabolism and Disposition*, **2003**, 31, 1093-102 | 4 | 72 |
| 201 | A 21st century roadmap for human health risk assessment. *Critical Reviews in Toxicology*, **2014**, 44 Suppl 3, 1-5 | 5.7 | 70 |
| 200 | A tiered approach to systemic toxicity testing for agricultural chemical safety assessment. *Critical Reviews in Toxicology*, **2006**, 36, 37-68 | 5.7 | 70 |
| 199 | Effect of cruciferous vegetable consumption on heterocyclic aromatic amine metabolism in man. *Carcinogenesis*, **2001**, 22, 1413-20 | 4.6 | 70 |
| 198 | Differential induction of antipyrine metabolism by rifampicin. *European Journal of Clinical Pharmacology*, **1981**, 21, 155-60 | 2.8 | 70 |
| 197 | Expression of CYP1A1, CYP1B1 and CYP3A, and polycyclic aromatic hydrocarbon-DNA adduct formation in bronchoalveolar macrophages of smokers and non-smokers. *International Journal of Cancer*, **2000**, 86, 610-6 | 7.5 | 69 |
| 196 | The inducibility and catalytic activity of cytochromes P450c (P450IA1) and P450d (P450IA2) in rat tissues. *Biochemical Pharmacology*, **1990**, 39, 499-506 | 6 | 68 |
| 195 | Mutational spectra of the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine(PhIP) at the Chinese hamsters hprt locus. *Carcinogenesis*, **1996**, 17, 617-24 | 4.6 | 67 |
| 194 | Human hepatic CYP1A1 and CYP1A2 content, determined with specific anti-peptide antibodies, correlates with the mutagenic activation of PhIP. *Carcinogenesis*, **1993**, 14, 585-92 | 4.6 | 67 |
| 193 | Adverse Outcome Pathways can drive non-animal approaches for safety assessment. *Journal of Applied Toxicology*, **2015**, 35, 971-5 | 4.1 | 66 |
| 192 | Co-localization of P450 enzymes in the rat substantia nigra with tyrosine hydroxylase. *Neuroscience*, **1998**, 86, 511-9 | 3.9 | 66 |
| 191 | Expression and inducibility of P450 enzymes during liver ontogeny. *Microscopy Research and Technique*, **1997**, 39, 424-35 | 2.8 | 65 |
| 190 | Thresholds of Toxicological Concern for cosmetics-related substances: New database, thresholds, and enrichment of chemical space. *Food and Chemical Toxicology*, **2017**, 109, 170-193 | 4.7 | 64 |
| 189 | Genetic polymorphism in drug oxidation: in vitro studies of human debrisoquine 4-hydroxylase and bufuralol 1'-hydroxylase activities. *Biochemical Pharmacology*, **1985**, 34, 65-71 | 6 | 64 |
| 188 | Determination of a human hepatic microsomal scaling factor for predicting in vivo drug clearance. *Pharmaceutical Research*, **2006**, 23, 533-9 | 4.5 | 59 |
| 187 | Cytochrome P450 3A expression in the human fetal liver: evidence that CYP3A5 is expressed in only a limited number of fetal livers. *Neonatology*, **2001**, 80, 193-201 | 4 | 58 |

| | | | |
|---|---|---|---|
| 186 | PGC-1α controls mitochondrial biogenesis and dynamics in lead-induced neurotoxicity. *Aging*, **2015**, 7, 629-47 | 5.6 | 57 |
| 185 | Effect of isoniazid on vitamin D metabolism and hepatic monooxygenase activity. *Clinical Pharmacology and Therapeutics*, **1981**, 30, 363-7 | 6.1 | 57 |
| 184 | The cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice. *European Journal of Clinical Pharmacology*, **1997**, 52, 311-5 | 2.8 | 56 |
| 183 | The role of hazard- and risk-based approaches in ensuring food safety. *Trends in Food Science and Technology*, **2015**, 46, 176-188 | 15.3 | 54 |
| 182 | The use of mode of action information in risk assessment: quantitative key events/dose-response framework for modeling the dose-response for key events. *Critical Reviews in Toxicology*, **2014**, 44 Suppl 3, 17-43 | 5.7 | 54 |
| 181 | Strategies to assess systemic exposure of chemicals in subchronic/chronic diet and drinking water studies. *Toxicology and Applied Pharmacology*, **2006**, 211, 245-60 | 4.6 | 54 |
| 180 | Expression of CYP2E1 during human fetal development: methylation of the CYP2E1 gene in human fetal and adult liver samples. *Biochemical Pharmacology*, **1992**, 43, 1876-9 | 6 | 53 |
| 179 | Immunohistochemical localization of cytochrome P450b/e in hepatic and extrahepatic tissues of the rat. *Biochemical Pharmacology*, **1989**, 38, 3305-22 | 6 | 52 |
| 178 | Classification schemes for carcinogenicity based on hazard-identification have become outmoded and serve neither science nor society. *Regulatory Toxicology and Pharmacology*, **2016**, 82, 158-166 | 3.4 | 51 |
| 177 | Carbamazepine: a 'blind' assessment of CVP-associated metabolism and interactions in human liver-derived in vitro systems. *Xenobiotica*, **2001**, 31, 321-43 | 2 | 51 |
| 176 | Thiazopyr and thyroid disruption: case study within the context of the 2006 IPCS Human Relevance Framework for analysis of a cancer mode of action. *Critical Reviews in Toxicology*, **2006**, 36, 793-801 | 5.7 | 49 |
| 175 | In vitro prediction of gastrointestinal absorption and bioavailability: an experts' meeting report. *European Journal of Clinical Pharmacology*, **2001**, 57, 621-9 | 2.8 | 49 |
| 174 | High affinity phenacetin O-deethylase is catalysed specifically by cytochrome P450d (P450IA2) in the liver of the rat. *Biochemical Pharmacology*, **1990**, 39, 489-98 | 6 | 49 |
| 173 | Polymorphic debrisoquine 4-hydroxylase activity in the rat is due to differences in CYP2D2 expression. *Pharmacogenetics and Genomics*, **1999**, 9, 357-66 | | 48 |
| 172 | Selective localisation of P450 enzymes and NADPH-P450 oxidoreductase in rat basal ganglia using anti-peptide antisera. *Brain Research*, **1996**, 743, 324-8 | 3.7 | 48 |
| 171 | Paracetamol oxidation: synthesis and reactivity of N-acetyl-p-benzoquinoneimine. *Tetrahedron Letters*, **1980**, 21, 4947-4950 | 2 | 48 |
| 170 | N-hydroxy-MeIQx is the major microsomal oxidation product of the dietary carcinogen MeIQx with human liver. *Carcinogenesis*, **1992**, 13, 2221-6 | 4.6 | 47 |
| 169 | An evaluation framework for new approach methodologies (NAMs) for human health safety assessment. *Regulatory Toxicology and Pharmacology*, **2020**, 112, 104592 | 3.4 | 46 |

| | | | |
|---|---|---|---|
| 168 | Physiologically-based Kinetic Modelling (PBK Modelling): meeting the 3Rs agenda. The report and recommendations of ECVAM Workshop 63. *ATLA Alternatives To Laboratory Animals*, **2007**, 35, 661-71 | 2.1 | 46 |
| 167 | Short synthetic peptides exploited for reliable and specific targeting of antibodies to the C-termini of cytochrome P450 enzymes. *Biochemical Pharmacology*, **1995**, 49, 39-47 | 6 | 46 |
| 166 | Agricultural chemical safety assessment: A multisector approach to the modernization of human safety requirements. *Critical Reviews in Toxicology*, **2006**, 36, 1-7 | 5.7 | 45 |
| 165 | Evidence for a direct role of intracellular calcium in paracetamol toxicity. *Biochemical Pharmacology* , **1990**, 39, 1277-81 | 6 | 45 |
| 164 | Assessment of diurnal systemic dose of agrochemicals in regulatory toxicity testing--an integrated approach without additional animal use. *Regulatory Toxicology and Pharmacology*, **2012**, 63, 321-32 | 3.4 | 44 |
| 163 | Using mode of action information to improve regulatory decision-making: an ECETOC/ILSI RF/HESI workshop overview. *Critical Reviews in Toxicology*, **2011**, 41, 175-86 | 5.7 | 44 |
| 162 | Considering new methodologies in strategies for safety assessment of foods and food ingredients. *Food and Chemical Toxicology*, **2016**, 91, 19-35 | 4.7 | 43 |
| 161 | BRAFO tiered approach for Benefit-Risk Assessment of Foods. *Food and Chemical Toxicology*, **2012**, 50 Suppl 4, S684-98 | 4.7 | 42 |
| 160 | Chemical carcinogenicity revisited 3: Risk assessment of carcinogenic potential based on the current state of knowledge of carcinogenesis in humans. *Regulatory Toxicology and Pharmacology*, **2019**, 103, 100-105 | 3.4 | 42 |
| 159 | Paracetamol metabolism, hepatotoxicity, biomarkers and therapeutic interventions: a perspective. *Toxicology Research*, **2018**, 7, 347-357 | 2.6 | 41 |
| 158 | Drug interactions. *Drug Metabolism Reviews*, **2009**, 41, 486-527 | 7 | 41 |
| 157 | A data-based assessment of alternative strategies for identification of potential human cancer hazards. *Toxicologic Pathology*, **2009**, 37, 714-32 | 2.1 | 40 |
| 156 | Risk assessment of contaminants in food and feed. *EFSA Journal*, **2012**, 10, s1004 | 2.3 | 40 |
| 155 | Differential induction of murine Ah locus-associated monooxygenase activities in rabbit liver and kidney. *Biochemical Pharmacology*, **1975**, 24, 2111-6 | 6 | 40 |
| 154 | Evolution of chemical-specific adjustment factors (CSAF) based on recent international experience; increasing utility and facilitating regulatory acceptance. *Critical Reviews in Toxicology*, **2017**, 47, 729-749 | 5.7 | 39 |
| 153 | 4-Aminobiphenyl and DNA reactivity: case study within the context of the 2006 IPCS Human Relevance Framework for Analysis of a cancer mode of action for humans. *Critical Reviews in Toxicology*, **2006**, 36, 803-19 | 5.7 | 39 |
| 152 | Determination of the N-acetyl metabolites of 4,4'-methylene dianiline and 4,4'-methylene-bis(2-chloroaniline) in urine. *Biological Mass Spectrometry*, **1988**, 17, 161-7 | | 39 |
| 151 | Chemical carcinogenicity revisited 1: A unified theory of carcinogenicity based on contemporary knowledge. *Regulatory Toxicology and Pharmacology*, **2019**, 103, 86-92 | 3.4 | 39 |

| | | | |
|---|---|---|---|
| 150 | A framework for cumulative risk assessment in the 21st century. *Critical Reviews in Toxicology*, **2017**, 47, 85-97 | 5.7 | 38 |
| 149 | Antibodies to a synthetic peptide that react specifically with a common surface region on two hydrocarbon-inducible isoenzymes of cytochrome P-450 in the rat. *Biochemical Pharmacology*, **1988**, 37, 3735-41 | 6 | 38 |
| 148 | Establishing the level of safety concern for chemicals in food without the need for toxicity testing. *Regulatory Toxicology and Pharmacology*, **2014**, 68, 275-96 | 3.4 | 37 |
| 147 | Use of toxicokinetics to support chemical evaluation: Informing high dose selection and study interpretation. *Regulatory Toxicology and Pharmacology*, **2012**, 62, 241-7 | 3.4 | 36 |
| 146 | A proposed framework for assessing risk from less-than-lifetime exposures to carcinogens. *Critical Reviews in Toxicology*, **2011**, 41, 507-44 | 5.7 | 36 |
| 145 | Human relevance of rodent liver tumors: Key insights from a Toxicology Forum workshop on nongenotoxic modes of action. *Regulatory Toxicology and Pharmacology*, **2018**, 92, 1-7 | 3.4 | 36 |
| 144 | Elucidation of toxicity pathways in lung epithelial cells induced by silicon dioxide nanoparticles. *PLoS ONE*, **2013**, 8, e72363 | 3.7 | 34 |
| 143 | Application of the TTC concept to unknown substances found in analysis of foods. *Food and Chemical Toxicology*, **2011**, 49, 1643-60 | 4.7 | 34 |
| 142 | Local kinetics and dynamics of xenobiotics. *Critical Reviews in Toxicology*, **2008**, 38, 697-720 | 5.7 | 34 |
| 141 | Polymorphic metabolism of the carcinogen 2-acetylaminofluorene in human liver microsomes. *Carcinogenesis*, **1985**, 6, 1721-4 | 4.6 | 34 |
| 140 | Comparative physicochemical and pharmacokinetic profiles of inhaled beclomethasone dipropionate and budesonide. *Respiratory Medicine*, **1998**, 92 Suppl B, 2-6 | 4.6 | 33 |
| 139 | Evidence for nitric oxide participation in down-regulation of CYP2B1/2 gene expression at the pretranslational level. *Toxicology Letters*, **1997**, 90, 207-16 | 4.4 | 32 |
| 138 | Genetic analysis of PHIP intestinal mutations in MutaMouse. *Mutagenesis*, **1998**, 13, 601-5 | 2.8 | 31 |
| 137 | Chemical carcinogenicity revisited 2: Current knowledge of carcinogenesis shows that categorization as a carcinogen or non-carcinogen is not scientifically credible. *Regulatory Toxicology and Pharmacology*, **2019**, 103, 124-129 | 3.4 | 30 |
| 136 | An F1-extended one-generation reproductive toxicity study in Crl:CD(SD) rats with 2,4-dichlorophenoxyacetic acid. *Toxicological Sciences*, **2013**, 136, 527-47 | 4.4 | 30 |
| 135 | Genetic and other sources of variation in the activity of serum paraoxonase/diazoxonase in humans: consequences for risk from exposure to diazinon. *Pharmacogenetics and Genomics*, **2005**, 15, 51-60 | 1.9 | 30 |
| 134 | The mutagenicity of benzo[a]pyrene in mouse small intestine. *Carcinogenesis*, **1999**, 20, 109-14 | 4.6 | 30 |
| 133 | How well can carcinogenicity be predicted by high throughput "characteristics of carcinogens" mechanistic data?. *Regulatory Toxicology and Pharmacology*, **2017**, 90, 185-196 | 3.4 | 29 |

| | | | |
|---|---|---|---|
| 132 | Expression of CYP3A4 in human breast tumour and non-tumour tissues. *Cancer Letters*, **2003**, 202, 17-23 | 9.9 | 29 |
| 131 | Identification of the epitope of an anti-peptide antibody which binds to CYP1A2 in many species including man. *Biochemical Pharmacology*, **1993**, 46, 213-20 | 6 | 29 |
| 130 | Bufuralol 1'-hydroxylase activity of the rat. Strain differences and the effects of inhibitors. *Biochemical Pharmacology*, **1986**, 35, 2961-5 | 6 | 29 |
| 129 | Genetic differences in the metabolic activation of benzo[a]pyrene in mice. Attempts to correlate tumorigenesis with binding of reactive intermediates to DNA and with mutagenesis in vitro. *Pharmacology*, **1979**, 18, 281-93 | 2.3 | 29 |
| 128 | Life-stage-, sex-, and dose-dependent dietary toxicokinetics and relationship to toxicity of 2,4-dichlorophenoxyacetic acid (2,4-D) in rats: implications for toxicity test dose selection, design, and interpretation. *Toxicological Sciences*, **2013**, 136, 294-307 | 4.4 | 28 |
| 127 | Kinetics of lung macrophages monitored in vivo following particulate challenge in rabbits. *Toxicology and Applied Pharmacology*, **2002**, 183, 46-54 | 4.6 | 28 |
| 126 | Immunohistochemical demonstration of the expression of CYP2E1 in human breast tumour and non-tumour tissues. *Cancer Letters*, **2003**, 196, 153-9 | 9.9 | 28 |
| 125 | Rapid tolerance to the hypotensive effects of glyceryl trinitrate in the rat: prevention by N-acetyl-L- but not N-acetyl-D-cysteine. *British Journal of Pharmacology*, **1990**, 99, 825-9 | 8.6 | 28 |
| 124 | Origin of the TTC values for compounds that are genotoxic and/or carcinogenic and an approach for their re-evaluation. *Critical Reviews in Toxicology*, **2017**, 47, 705-727 | 5.7 | 27 |
| 123 | Human health and endocrine disruption: a simple multicriteria framework for the qualitative assessment of end point specific risks in a context of scientific uncertainty. *Toxicological Sciences*, **2007**, 98, 332-47 | 4.4 | 27 |
| 122 | Effects of microsomal enzyme inducers in vivo and inhibitors in vitro on the covalent binding of benzo[a]pyrene metabolites to DNA catalyzed by liver microsomes from genetically responsive and nonresponsive mice. *Biochemical Pharmacology*, **1979**, 28, 111-21 | 6 | 27 |
| 121 | Assessing human risk to heterocyclic amines. *Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis*, **1997**, 376, 53-60 | 3.3 | 26 |
| 120 | Expression of P450 enzymes in rat whole skin and cultured epidermal keratinocytes. *Biochemical and Biophysical Research Communications*, **2002**, 297, 65-70 | 3.4 | 26 |
| 119 | Critical appraisal of the assessment of benefits and risks for foods, 'BRAFO Consensus Working Group'. *Food and Chemical Toxicology*, **2013**, 55, 659-75 | 4.7 | 25 |
| 118 | A sensitive and robust method for the determination of alkylphenol polyethoxylates and their carboxylic acids and their transformation in a trickling filter wastewater treatment plant. *Chemosphere*, **2008**, 73, 551-6 | 8.4 | 25 |
| 117 | Expression of cytochromes P450 3A and P-glycoprotein in human large intestine in paired tumour and normal samples. *Basic and Clinical Pharmacology and Toxicology*, **2007**, 100, 240-8 | 3.1 | 25 |
| 116 | Expression and localisation of CYP2D enzymes in rat basal ganglia. *Brain Research*, **1999**, 822, 175-91 | 3.7 | 24 |
| 115 | A monoclonal antibody raised to rat liver cytochrome P-448 (form C) which recognises an epitope common to many other forms of cytochrome P-450. *Biochemical Pharmacology*, **1985**, 34, 1671-81 | 6 | 24 |

| | | | |
|---|---|---|---|
| 114 | Problem formulation for risk assessment of combined exposures to chemicals and other stressors in humans. *Critical Reviews in Toxicology*, **2016**, 46, 835-844 | 5.7 | 24 |
| 113 | Molecular approaches to the identification of biomarkers of exposure and effect--report of an expert meeting organized by COST Action B15. November 28, 2003. *Toxicology Letters*, **2005**, 156, 227-40 | 4.4 | 23 |
| 112 | Adduction of the chloroform metabolite phosgene to lysine residues of human histone H2B. *Chemical Research in Toxicology*, **2003**, 16, 266-75 | 4 | 23 |
| 111 | Antipyrine elimination in patients with obstructive jaundice: a predictor of outcome. *American Journal of Surgery*, **1985**, 149, 140-3 | 2.7 | 23 |
| 110 | Cross-reaction of antibodies to coupling groups used in the production of anti-peptide antibodies. *Journal of Immunological Methods*, **1989**, 117, 215-20 | 2.5 | 22 |
| 109 | Building a developmental toxicity ontology. *Birth Defects Research*, **2018**, 110, 502-518 | 2.9 | 21 |
| 108 | Evaluation of the utility of the lifetime mouse bioassay in the identification of cancer hazards for humans. *Food and Chemical Toxicology*, **2013**, 60, 550-62 | 4.7 | 21 |
| 107 | Increased expression of histone proteins during estrogen-mediated cell proliferation. *Environmental Health Perspectives*, **2009**, 117, 928-34 | 8.4 | 21 |
| 106 | Identification of estrogen-responsive proteins in MCF-7 human breast cancer cells using label-free quantitative proteomics. *Proteomics*, **2008**, 8, 1987-2005 | 4.8 | 21 |
| 105 | Current knowledge and recent developments in consumer exposure assessment of pesticides: a UK perspective. *Food Additives and Contaminants*, **2002**, 19, 837-52 | | 20 |
| 104 | Interlaboratory comparison of the assessment of P450 activities in human hepatic microsomal samples. *Xenobiotica*, **1998**, 28, 493-506 | 2 | 20 |
| 103 | Antipeptide antibodies in studies of cytochromes P450IA. *Methods in Enzymology*, **1991**, 206, 220-33 | 1.7 | 20 |
| 102 | Combined assay for phenacetin and paracetamol in plasma using capillary column gas chromatography-negative-ion mass spectrometry. *Biomedical Applications*, **1991**, 568, 341-50 | | 20 |
| 101 | Risk Benefit Assessment of foods: Key findings from an international workshop. *Food Research International*, **2019**, 116, 859-869 | 7 | 20 |
| 100 | Selection of appropriate tumour data sets for Benchmark Dose Modelling (BMD) and derivation of a Margin of Exposure (MoE) for substances that are genotoxic and carcinogenic: considerations of biological relevance of tumour type, data quality and uncertainty assessment. *Food and Chemical Toxicology*, **2014**, 70, 264-89 | 4.7 | 19 |
| 99 | The dose makes the poison: Key implications for mode of action (mechanistic) research in a 21st century toxicology paradigm. *Current Opinion in Toxicology*, **2017**, 3, 87-91 | 4.4 | 19 |
| 98 | Rapid analysis for metabolites of 11C-labelled drugs: fate of [11C]-S-4-(tert.-butylamino-2-hydroxypropoxy)-benzimidazol-2-one in the dog. *Biomedical Applications*, **1991**, 570, 361-70 | | 19 |
| 97 | The selective activation of cytochrome P-450 dependent microsomal hydroxylases in human and rat liver microsomes. *Biochemical Pharmacology*, **1981**, 30, 1702-3 | 6 | 19 |

| | | | |
|---|---|---|---|
| 96 | Effect of washing the hepatic microsomal fraction in sucrose solutions and in sucrose solution containing EDTA upon the metabolism of foreign compounds. *Biochemical Pharmacology*, **1975**, 24, 1771-6 | 6 | 19 |
| 95 | Characterizing chronic and acute health risks of residues of veterinary drugs in food: latest methodological developments by the joint FAO/WHO expert committee on food additives. *Critical Reviews in Toxicology*, **2017**, 47, 885-899 | 5.7 | 18 |
| 94 | The significance of sample mass in the analysis of steroid estrogens in sewage sludges and the derivation of partition coefficients in wastewaters. *Journal of Chromatography A*, **2009**, 1216, 4923-6 | 4.5 | 18 |
| 93 | Mass spectrometric detection and measurement of N2-(2'-deoxyguanosin-8-yl)PhIP adducts in DNA. *Biomedical Applications*, **2000**, 744, 55-64 | | 18 |
| 92 | Mechanisms of cell toxicity. *Current Opinion in Cell Biology*, **1990**, 2, 231-7 | 9 | 18 |
| 91 | Dissecting the function of cytochrome P450. *British Journal of Clinical Pharmacology*, **1996**, 42, 81-9 | 3.8 | 17 |
| 90 | Assessment of P450 induction in the marmoset monkey using targeted anti-peptide antibodies. *BBA - Proteins and Proteomics*, **2001**, 1546, 143-55 | | 16 |
| 89 | Exposure to and activation of dietary heterocyclic amines in humans. *Critical Reviews in Oncology/Hematology*, **1995**, 21, 19-31 | 7 | 16 |
| 88 | Paracetamol toxicity in hamster isolated hepatocytes: the increase in cytosolic calcium accompanies, rather than precedes, loss of viability. *Archives of Toxicology*, **1992**, 66, 408-12 | 5.8 | 16 |
| 87 | Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer. *Oncotarget*, **2016**, 7, 44505-44521 | 3.3 | 16 |
| 86 | Immunopurification of cytochrome P-448 from microsomal fractions of rabbit liver with retention of metabolic activity. *Biochemical Pharmacology*, **1982**, 31, 1815-7 | 6 | 15 |
| 85 | IARC use of oxidative stress as key mode of action characteristic for facilitating cancer classification: Glyphosate case example illustrating a lack of robustness in interpretative implementation. *Regulatory Toxicology and Pharmacology*, **2017**, 86, 157-166 | 3.4 | 14 |
| 84 | Guidance for the classification of carcinogens under the Globally Harmonised System of Classification and Labelling of Chemicals (GHS). *Critical Reviews in Toxicology*, **2010**, 40, 245-85 | 5.7 | 14 |
| 83 | Cancer Research UK procedures in manufacture and toxicology of radiotracers intended for pre-phase I positron emission tomography studies in cancer patients. *British Journal of Cancer*, **2002**, 86, 1052-6 | 8.7 | 14 |
| 82 | Expression and distribution of CYP2C enzymes in rat basal ganglia. *Synapse*, **2000**, 38, 392-402 | 2.4 | 14 |
| 81 | DNA binding of benzo[a]pyrene metabolites. Effects of substrate and microsomal protein concentration in vitro, dietary contaminants, and tissue differences. *Pharmacology*, **1980**, 20, 137-48 | 2.3 | 14 |
| 80 | A mode-of-action ontology model for safety evaluation of chemicals: Outcome of a series of workshops on repeated dose toxicity. *Toxicology in Vitro*, **2019**, 59, 44-50 | 3.6 | 13 |
| 79 | Assessment of uncertainty in a probabilistic model of consumer exposure to pesticide residues in food. *Food Additives and Contaminants*, **2006**, 23, 601-15 | | 13 |

| | | | |
|---|---|---|---|
| 78 | A strategy for investigating the CYP superfamily using targeted antibodies is a paradigm for functional genomic studies. *Drug Metabolism and Disposition*, **2003**, 31, 1476-80 | 4 | 13 |
| 77 | The effects of catecholamines upon the metabolism of foreign compounds and upon the distribution of perfusate in the isolated liver of the rat. *Biochemical Pharmacology*, **1974**, 23, 3377-84 | 6 | 12 |
| 76 | Enzymic and interindividual differences in the human metabolism of heterocyclic amines. *Archives of Toxicology Supplement*, **1996**, 18, 286-302 | | 12 |
| 75 | Value and limitation of bioassays to support the application of the threshold of toxicological concern to prioritise unidentified chemicals in food contact materials. *Food Additives and Contaminants - Part A Chemistry, Analysis, Control, Exposure and Risk Assessment*, **2019**, 36, 1903-1936 | 3.2 | 11 |
| 74 | Target organ profiles in toxicity studies supporting human dosing: Does severity progress with longer duration of exposure?. *Regulatory Toxicology and Pharmacology*, **2015**, 73, 737-46 | 3.4 | 11 |
| 73 | A framework for fit-for-purpose dose response assessment. *Regulatory Toxicology and Pharmacology*, **2013**, 66, 234-40 | 3.4 | 11 |
| 72 | Positron emission tomography in the quantification of cellular and biochemical responses to intrapulmonary particulates. *Toxicology and Applied Pharmacology*, **2005**, 207, 230-6 | 4.6 | 11 |
| 71 | The effect of pretreating rats with 3-methylcholanthrene upon the enhancement of microsomal aniline hydroxylation by acetone and other agents. *Biochemical Pharmacology*, **1975**, 24, 424-6 | 6 | 11 |
| 70 | Relevance of mouse lung tumors to human risk assessment. *Journal of Toxicology and Environmental Health - Part B: Critical Reviews*, **2020**, 23, 214-241 | 8.6 | 11 |
| 69 | E2F1-mediated FOS induction in arsenic trioxide-induced cellular transformation: effects of global H3K9 hypoacetylation and promoter-specific hyperacetylation in vitro. *Environmental Health Perspectives*, **2015**, 123, 484-92 | 8.4 | 10 |
| 68 | Characterizing the coverage of critical effects relevant in the safety evaluation of food additives by AOPs. *Archives of Toxicology*, **2019**, 93, 2115-2125 | 5.8 | 10 |
| 67 | Testicular dysgenesis syndrome and the estrogen hypothesis: a quantitative meta-analysis. *Ciencia E Saude Coletiva*, **2008**, 13, 1601-18 | 2.2 | 10 |
| 66 | Drug oxidation in Asian vegetarians. *Lancet, The*, **1980**, 2, 151 | 40 | 10 |
| 65 | Interpretation of the margin of exposure for genotoxic carcinogens - elicitation of expert knowledge about the form of the dose response curve at human relevant exposures. *Food and Chemical Toxicology*, **2013**, 57, 106-18 | 4.7 | 9 |
| 64 | Inhibition of human CYP1A2 activity in vitro by methylxanthines: potent competitive inhibition by 8-phenyltheophylline. *Xenobiotica*, **2001**, 31, 135-51 | 2 | 9 |
| 63 | Genetic differences in the metabolism of carcinogens and in the binding of benzo (a) pyrene metabolites to DNA. *Advances in Enzyme Regulation*, **1976**, 15, 339-62 | | 9 |
| 62 | Fate and occurrence of alkylphenolic compounds in sewage sludges determined by liquid chromatography tandem mass spectrometry. *Environmental Technology (United Kingdom)*, **2009**, 30, 1415-24 | 2.6 | 8 |
| 61 | Identification of the epitope of a monoclonal antibody which binds to several cytochromes P450 in the CYP1A subfamily. *Biochemical Pharmacology*, **1992**, 43, 1737-46 | 6 | 8 |

| | | | |
|---|---|---|---|
| 60 | An inhibitory monoclonal anti-protein antibody and an anti-peptide antibody share an epitope on rat cytochrome P-450 enzymes CYP1A1 and CYP1A2. *BBA - Proteins and Proteomics*, **1993**, 1161, 38-46 | | 8 |
| 59 | Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?. *Journal of Toxicology and Environmental Health - Part A: Current Issues*, **2020**, 83, 485-494 | 3.2 | 7 |
| 58 | Effects of mid-respiratory chain inhibition on mitochondrial function and. *Toxicology Research*, **2016**, 5, 136-150 | 2.6 | 7 |
| 57 | Mode of action considerations in the quantitative assessment of tumour responses in the liver. *Basic and Clinical Pharmacology and Toxicology*, **2010**, 106, 173-9 | 3.1 | 7 |
| 56 | Proteomic analysis of human breast cell lines using SELDI-TOF MS shows that mixtures of estrogenic compounds exhibit simple similar action (concentration additivity). *Toxicology Letters*, **2008**, 181, 93-103 | 4.4 | 7 |
| 55 | Re: Guyton, Kathryn Z., Barone, Stanley, Jr., Brown, Rebecca C., Euling, Susan Y., Jinot, Jennifer, Makris, Susan (2008). Mode of action frameworks: a critical analysis. Journal of Toxicology and Environmental Health, Part B, 11(1): 16-31. *Journal of Toxicology and Environmental Health - Part B: Critical Reviews*, **2008**, 11, 681-3; author reply 684-5 | 8.6 | 7 |
| 54 | Assay of caffeine metabolism in vitro by human liver microsomes using radio-high-performance liquid chromatography. *Journal of Pharmaceutical and Biomedical Analysis*, **1990**, 8, 783-7 | 3.5 | 7 |
| 53 | Catecholamine turnover in essential hypertension. *Clinical and Experimental Hypertension*, **1980**, 2, 395-408 | | 7 |
| 52 | A rapid sensitive assay for glutathione S-epoxidetransferase activity: species differences in the activity of the hepatic enzyme [proceedings]. *Biochemical Society Transactions*, **1979**, 7, 1060-1 | 5.1 | 7 |
| 51 | Effects of pharmaceuticals and other active chemicals at biological targets: mechanisms, interactions, and integration into PB-PK/PD models. *Expert Opinion on Therapeutic Targets*, **2009**, 13, 867-87 | 6.4 | 6 |
| 50 | Specific inhibition of human CYP1A2 using a targeted antibody. *Biochemical Pharmacology*, **1997**, 54, 189-97 | 6 | 6 |
| 49 | C-terminal antibodies (CTAbs): a simple and broadly applicable approach for the rapid generation of protein-specific antibodies with predefined specificity. *Proteomics*, **2007**, 7, 1364-72 | 4.8 | 6 |
| 48 | Urinary N2-(2'-deoxyguanosin-8-yl)PhIP as a biomarker for PhIP exposure. *Carcinogenesis*, **2004**, 25, 1053-62 | 4.2 | 6 |
| 47 | Is the activation of aflatoxin B1 catalysed by the same form of cytochrome P-450 as that 4-hydroxylating debrisoquine in rat and/or man?. *Archives of Toxicology*, **1986**, 58, 165-70 | 5.8 | 6 |
| 46 | Multiple forms of human cytochrome P-450. *Biochemical Society Transactions*, **1984**, 12, 78-80 | 5.1 | 6 |
| 45 | Stereoselective excretion of (3-methoxy-4-sulphooxyphenyl)ethylene glycol (MHPG sulphate) in the dog. *Naunyn-Schmiedebergfs Archives of Pharmacology*, **1980**, 314, 89-96 | 3.4 | 6 |
| 44 | Harmonized methodology to assess chronic dietary exposure to residues from compounds used as pesticide and veterinary drug. *Critical Reviews in Toxicology*, **2019**, 49, 1-10 | 5.7 | 5 |
| 43 | Upholding science in health, safety and environmental risk assessments and regulations. *Toxicology*, **2016**, 371, 12-16 | 4.4 | 5 |

| | | | |
|---|---|---|---|
| 42 | Human health screening level risk assessments of tertiary-butyl acetate (TBAC): calculated acute and chronic reference concentration (RfC) and Hazard Quotient (HQ) values based on toxicity and exposure scenario evaluations. *Critical Reviews in Toxicology*, **2015**, 45, 142-71 | 5.7 | 5 |
| 41 | Species differences in the hepatic formation of green pigments following the administration of norethindrone. *Biochemical Pharmacology*, **1984**, 33, 459-64 | 6 | 5 |
| 40 | Induction of aryl hydrocarbon (benzo[a]pyrene) hydroxylase and 2-acetylaminofluorene N-hydroxylase by polycyclic hydrocarbons in regenerating liver from inbred strains of mice. *Biochemical Pharmacology*, **1977**, 26, 1501-5 | 6 | 5 |
| 39 | Use of the kinetically-derived maximum dose: Opportunities for delivering 3Rs benefits. *Regulatory Toxicology and Pharmacology*, **2020**, 116, 104734 | 3.4 | 5 |
| 38 | Risk assessments for chronic exposure of children and prospective parents to ethylbenzene (CAS No. 100-41-4). *Critical Reviews in Toxicology*, **2015**, 45, 662-726 | 5.7 | 4 |
| 37 | Hazard identification, classification, and risk assessment of carcinogens: too much or too little? - Report of an ECETOC workshop. *Critical Reviews in Toxicology*, **2020**, 50, 72-95 | 5.7 | 4 |
| 36 | IPCS framework for analysing the relevance of a cancer mode of action for humans. *Toxicology Letters*, **2006**, 164, S254-S255 | 4.4 | 4 |
| 35 | Molecular basis for differences in susceptibility to toxicants: introduction. *Toxicology Letters*, **1992**, 64-65 Spec No, 109-13 | 4.4 | 4 |
| 34 | The metabolic activation of 4,4'-methylene-bis-(2-chlorobenzeneamine) to a bacterial mutagen by hepatic postmitochondrial supernatant from human and other species. *Environmental Mutagenesis*, **1985**, 7, 501-9 | | 4 |
| 33 | Ethanol protection against hemicholinium toxicity in mice. *Biochemical Pharmacology*, **1975**, 24, 485-8 | 6 | 4 |
| 32 | Opportunities and challenges related to saturation of toxicokinetic processes: Implications for risk assessment. *Regulatory Toxicology and Pharmacology*, **2021**, 127, 105070 | 3.4 | 4 |
| 31 | Risk assessment of dietary supplements. *Novartis Foundation Symposium*, **2007**, 282, 3-25; discussion 25-8, 212-8 | | 4 |
| 30 | Improving selection of markers in nutrition research: evaluation of the criteria proposed by the ILSI Europe Marker Validation Initiative. *Nutrition Research Reviews*, **2017**, 30, 73-81 | 7 | 3 |
| 29 | Use of protein profiles to characterise concentration□effect curves of mixtures of estrogenic compounds in human breast cell lines. *Toxicology Letters*, **2006**, 164, S165-S166 | 4.4 | 3 |
| 28 | Differential expression of cytochrome P450 enzymes in cultured and intact foetal rat ventral mesencephalon. *Journal of Neural Transmission*, **2003**, 110, 1091-101 | 4.3 | 3 |
| 27 | Developmental changes in hepatic activation of 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline in rabbit. *Carcinogenesis*, **1996**, 17, 555-8 | 4.6 | 3 |
| 26 | Ontogeny of expression, inducibility and distribution of cytochromes P-450 forms 4 and 6 in rabbit liver. *Biochemical Society Transactions*, **1989**, 17, 1023-4 | 5.1 | 3 |
| 25 | Critical analysis of literature on low dose synergy for use of TTC in screening chemical mixtures for risk assessment. *Toxicology Letters*, **2009**, 189, S51 | 4.4 | 2 |

| | | | |
|---|---|---|---|
| 24 | Searching for novel biomarkers of centrally and peripehrally-acting neurotoxicants, using surface-enhanced laser desorption/ionisation-time-of-flight mass spectrometry (SELDI-TOF MS). *Food and Chemical Toxicology*, **2007**, 45, 2126-37 | 4.7 | 2 |
| 23 | The mutational signature of alpha-hydroxytamoxifen at Hprt locus in Chinese hamster cells. *Carcinogenesis*, **2002**, 23, 1947-52 | 4.6 | 2 |
| 22 | Brain cytochrome P450 in the rat. *Biochemical Society Transactions*, **1996**, 24, 52S | 5.1 | 2 |
| 21 | Activation of the food carcinogen 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline by hepatocytes. *Biochemical Society Transactions*, **1989**, 17, 734-735 | 5.1 | 2 |
| 20 | Identification of surface regions of cytochromes P-450 using anti-peptide antibodies. *Biochemical Society Transactions*, **1989**, 17, 1022-3 | 5.1 | 2 |
| 19 | Cytoprotective effects of 16,16-dimethyl prostaglandin E2 on paracetamol toxicity in isolated hepatocytes. *Biochemical Society Transactions*, **1988**, 16, 641-642 | 5.1 | 2 |
| 18 | Immunohistochemical localization of cytochrome P-450 b/e in hepatic and extrahepatic rat tissues. *Biochemical Society Transactions*, **1988**, 16, 642-643 | 5.1 | 2 |
| 17 | Adducts of the chloroform metabolite phosgene. *Advances in Experimental Medicine and Biology*, **2001**, 500, 129-32 | 3.6 | 2 |
| 16 | Response to Loomis et□al Comment on Boobis et□al. *Regulatory Toxicology and Pharmacology*, **2017**, 88, 358-359 | 3.4 | 1 |
| 15 | Instruments for assessing risk of bias and other methodological criteria of animal studies: omission of well-established methods. *Environmental Health Perspectives*, **2014**, 122, A66-7 | 8.4 | 1 |
| 14 | Interindividual variability in metabolic activation in humans in vivo. *Environmental Toxicology and Pharmacology*, **1996**, 2, 161-3 | 5.8 | 1 |
| 13 | Species differences in specificity of hydrocarbon-inducible forms of cytochrome P-450. *Biochemical Society Transactions*, **1989**, 17, 1021-2 | 5.1 | 1 |
| 12 | Interindividual Differences in Monooxygenase Activities of Human Liver **1984**, 109-153 | | 1 |
| 11 | Characterising vaping products in the United Kingdom: an analysis of Tobacco Products Directive notification data. *Addiction*, **2021**, 116, 2521-2528 | 4.6 | 1 |
| 10 | INDUSTRIAL PERSPECTIVES **2020**, 127-147 | | |
| 9 | Miscellaneous Chlorinated Hydrocarbon Pesticides **2012**, 429-469 | | |
| 8 | Authors response to Huff et al., □larifying carcinogenicity of ethylbenzene□*Regulatory Toxicology and Pharmacology*, **2010**, 58, 170-172 | 3.4 | |
| 7 | Analysis of the N-(deoxyguanosin-8-yl) adduct of the food derived carcinogen PhIP using capillary electrophoresis. *Biochemical Society Transactions*, **1997**, 25, 27S | 5.1 | |

| | | |
|---|---|---|
| 6 | The role of CYP1A enzymes in murine activation of the cooked food carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. *Biochemical Society Transactions*, **1994**, 22, 128S | 5.1 |
| 5 | Antibodies against rat cytochrome P-450d: comparison of the purified protein and a synthetic peptide as immunogens. *Biochemical Society Transactions*, **1989**, 17, 535-536 | 5.1 |
| 4 | 3,8-Dimethyl-2-nitro-imidazo[4,5-f]quinoxaline(Nitro-MeIQx) is a potent direct-acting mutagen. *Biochemical Society Transactions*, **1989**, 17, 540-541 | 5.1 |
| 3 | Hepatotoxicity of carbon tetrachloride: protection by pretreatment of mice with polyriboinosinic acid polyribocytidylic acid. *Biochemical Society Transactions*, **1988**, 16, 632-633 | 5.1 |
| 2 | The Effects of Trimethadione and Its Metabolite on Human Liver Debrisoquine 4-Hydroxylase Activity In Vitro. *The Showa University Journal of Medical Sciences*, **1990**, 2, 27-30 | 0.1 |
| 1 | Methyl-tert-butyl ether (MTBE): integration of rat and mouse carcinogenicity data with mode of action and human and rodent bioassay dosimetry and toxicokinetics indicates MTBE is not a plausible human carcinogen.. *Journal of Toxicology and Environmental Health - Part B: Critical Reviews*, **2022**, 1-27 | 8.6 |